[Erysipelatous inflammation: a new view on a long-standing problem].

Area of Science:

• Dermatology
• Infectious Diseases
• Pharmacology

Background:

• Erysipelatous inflammation, commonly known as erysipelas, is a bacterial skin infection often characterized by recurrent episodes.
• Managing and preventing recurrent erysipelas poses a clinical challenge, impacting patient quality of life.

Purpose of the Study:

• To evaluate the prophylactic efficacy of terbinafine hydrochloride (Lamisil) in preventing recurrent erysipelatous inflammation.

Main Methods:

• A study involving 72 patients with primary and recurring erysipelatous inflammation.
• Patients received antimitotic treatment with terbinafine hydrochloride.
• Recurrence rates were compared between the treatment group and a control group.

Main Results:

• Terbinafine hydrochloride demonstrated highly reliable effectiveness (p<0.001) in preventing recurrences.
• The recurrence frequency in the terbinafine hydrochloride treatment group was 7.1%.
• In contrast, the control group experienced a recurrence frequency of 45.5%.

Conclusions:

• Antimitotic treatment with terbinafine hydrochloride is a reliable prophylactic strategy for erysipelatous inflammation.
• This treatment significantly reduces the incidence of recurrent erysipelas.